Annals of clinical and translational neurologyOct 12, 2026

How Diabetes May Cause Thinking Problems and New Treatment Approaches

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 13, 2026

Abstract

Diabetes-associated cognitive impairment (DACI) is a common condition that can lead to neurodegeneration and dementia.

DACI includes patients who may develop vascular dementia or Alzheimer's disease as a result of diabetes.
In some cases, diabetes may primarily drive neurodegeneration without clear signs of vascular dementia or Alzheimer's.
DACI is characterized by disruptions in the neurovascular unit, impaired brain sugar metabolism, insulin resistance, and ongoing brain inflammation.
These mechanisms contribute to small blood vessel disease, regional brain shrinkage, and faster brain aging.
Potential treatments include GLP-1 receptor agonists and SGLT2 inhibitors, which may offer neuroprotective benefits.

Simplified

Diabetes-associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking clear VaD or AD features, diabetes may act as a primary driver of neurodegeneration. Mechanistically, DACI can be conceptualized as a neurovascular-metabolic disorder characterized by disruption of the neurovascular unit, impaired cerebral glucose metabolism, brain insulin resistance, and chronic neuroinflammation, contributing to small vessel disease, regional brain atrophy, and accelerated brain aging. In this narrative review, we synthesize current evidence on the clinical and imaging features of DACI, outline key mechanistic pathways linking diabetes to neurodegeneration, and discuss emerging therapeutic strategies, including GLP-1 receptor agonists and SGLT2 inhibitors, with potential neuroprotective effects. Greater recognition of DACI as a neurovascular-metabolic entity may facilitate earlier identification, inform biomarker development, and guide future trials aimed at preserving cognitive function in individuals with diabetes.

Full Text

Full text is available at the source.

View Full Text ↗

How Diabetes May Cause Thinking Problems and New Treatment Approaches

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief